⌘K
t
| Date | 6 Dec 2023 |
| Time | 12:41:41 |
| Category | Director/PDMR dealings |
| ID | 9067V |
6 December 2023
Scancell Holdings plc
("Scancell" or the "Company")
PDMR Notification
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that further to the Company's announcement on the 1 December 2023 regarding the successful placing of ordinary shares of nominal value of 0.1 pence in the Company ("Shares") and the subscription for Shares by Dr Jean-Michel Cosséry and Professor Lindy Durrant, the following Shares were issued on 5 December 2023:
Dr Jean-Michel Cosséry 454,545
Professor Lindy Durrant 272,727
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Jean-Michel Cosséry |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chairman of Board and PDMR |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Scancell Holdings plc |
|
b) |
LEI |
2138008RXEG856SNP666 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares |
|
b) |
Identification Code |
GB00B63D3314 |
|
c) |
Nature of the transaction |
Acquisition of ordinary shares |
|
|
|
|
|
d) |
Price(s) and volume(s) |
454,545 ordinary shares at £0.11 per share |
|
e) |
Aggregated information - Aggregated volume - Price |
N/A (single transaction)
|
|
f) |
Date of the transaction |
5 December 2023 |
|
g) |
Place of the transaction |
Outside a trading venue |
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Lindy Durant |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Director and PDMR |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Scancell Holdings plc |
|
b) |
LEI |
2138008RXEG856SNP666 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Acquisition of ordinary shares |
|
b) |
Identification Code |
GB00B63D3314 |
|
c) |
Nature of the transaction |
Acquisition of ordinary shares |
|
|
|
|
|
d) |
Price(s) and volume(s) |
272,727 ordinary shares at £0.11 per share
|
|
e) |
Aggregated information - Aggregated volume - Price |
N/A (single transaction)
|
|
f) |
Date of the transaction |
5 December 2023 |
|
g) |
Place of the transaction |
Outside a trading venue |
-ENDS-
|
For further information, please contact: |
|
|
|
|
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) |
+44 (0) 20 7710 7600 |
|
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking) |
|
|
Nick Adams/Nick Harland (Corporate Broking)
|
|
|
Panmure Gordon (UK) Limited (Joint Broker) |
+44 (0) 20 7886 2500 |
|
Freddy Crossley/Emma Earl (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking) |
|
|
ICR Consilium |
+44 (0) 20 3709 5700 |
|
Mary-Jane Elliott/Matthew Neal/Chris Welsh |
|
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
For further information about Scancell, please visit: https://www.scancell.co.uk/